Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32265
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOehler M.K.en
dc.contributor.authorFung A.en
dc.contributor.authorJobling T.W.en
dc.date.accessioned2021-05-14T10:55:42Zen
dc.date.available2021-05-14T10:55:42Zen
dc.date.copyright2005en
dc.date.created20050405en
dc.date.issued2012-10-17en
dc.identifier.citationJournal of the British Menopause Society. 11 (1) (pp 18-22), 2005. Date of Publication: March 2005.en
dc.identifier.issn1362-1807en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/32265en
dc.description.abstractEndometrial cancer (EC) most commonly affects postmenopausal women. It is curable if treated early, but tumours with adverse histopathological features or at an advanced stage are associated with a high mortality rate. These cancers require a complex therapeutic approach, consisting of surgery, radiotherapy, chemotherapy and/or hormonal therapy. As one of the leading causes of death from malignancy in women, EC has been subject to intense clinical investigation. This article examines recent advances in the surgical treatment of the disease, such as sentinel lymph node sampling and total laparoscopic hysterectomy, as well as topics such as conservative treatment of EC for fertility preservation. Furthermore, new agents for EC treatment are presented, for example inhibitors of the mTOR pathway and the angiogenesis-inhibitor VEGF-trap.en
dc.languageEnglishen
dc.languageenen
dc.publisherRoyal Society of Medicine Press Ltd (P.O. Box 9002, London W1A 0ZA, United Kingdom)en
dc.titleAdvances in the treatment of endometrial cancer.en
dc.typeReviewen
dc.type.studyortrialSystematic review and/or meta-analysis-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1258/1362180053654547en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid15814058 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15814058]en
dc.identifier.source40392766en
dc.identifier.institution(Oehler, Fung, Jobling) Dept. of Gynaecological Oncology, Monash Medical Centre, Moorabbin Campus, East Bentleigh, Vic. 3165, Australiaen
dc.description.addressM.K. Oehler, Dept. of Gynaecological Oncology, Monash Medical Centre, Moorabbin Campus, East Bentleigh, Vic. 3165, Australia. E-mail: Martin.Oehler@phimr.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsEndometrial cancer mTOR Sentinel lymph node Trastuzumab VEGF-trapen
dc.identifier.authoremailOehler M.K.; Martin.Oehler@phimr.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

2
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.